{"links":{"feed":"https://www.erudio.com/reports/rasolute-309-nct07805954/feed.json","html":"https://www.erudio.com/reports/rasolute-309-nct07805954","json":"https://www.erudio.com/reports/rasolute-309-nct07805954.json","markdown":"https://www.erudio.com/reports/rasolute-309-nct07805954.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rasolute-309-nct07805954"}},"request":"https://www.erudio.com/contact?report=rasolute-309-nct07805954"},"offer":{"cited_clinicians":10,"cited_commentary_sources":24,"verified_hcp_statements":25,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":15},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"rasolute-309-nct07805954"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rasolute-309-nct07805954","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rasolute-309-nct07805954","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 25 verified statements · 8 from 10 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-11T18:46:53.490918Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":0},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Progression free survival (PFS)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Overall survival (OS)"},{"claim_count":3,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":2,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":10,"title":"The comparison"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A8","source_count":3,"title":"Other public accounts' launch and pipeline interpretations"}],"counts":{"beyond_population_findings":6,"beyond_population_statements":114,"cited_clinicians":10,"cited_clinicians_by_role":{"physician":4,"physician, Medical oncology":6},"cited_physicians":10,"cited_sources":25,"claims_by_expression_type":{"comparison":1,"interpretation":5,"opinion":9,"primary_context":1,"question":3,"restatement":5,"uncertainty":1},"claims_by_kind":{"protocol_statement":1,"source_observation":24},"clinician_statements":8,"evidence_units":78,"findings":3,"organisational_accounts":3,"people_cited":17,"people_identity_verified":15,"people_total":17,"screened_sources":43,"verified_claims":25},"findings_index":[{"cited_clinicians":5,"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":2,"views":8},"limitations":2,"links":{"context":3,"support":17},"ma_question":true,"named_voices":6,"passages":13,"sources":12,"sources_by_kind":{"commentary":10,"media":1,"registry":1}},"title":"Speakers welcome a chemotherapy-free first-line possibility but await phase 3 confirmation"},{"cited_clinicians":0,"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":3,"views":0},"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"registry":1}},"title":"One LinkedIn account asks: why use GemNabTAX as the control rather than mFOLFIRINOX or nalIRINOX?"},{"cited_clinicians":1,"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"limitations":2,"links":{"context":1,"support":4},"ma_question":true,"named_voices":1,"passages":4,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"One LinkedIn account hopes for Brazilian study access; a UK account sees progress toward access"}],"open_question":{"basis":"From finding F1 (14 statements from 6 speakers in 12 sources)","cited_claim_ids":["claim-43dfe3ee5fe9dc8da63d","claim-0dc0e31f73f4b1678d25","claim-9a72af5732f8b86bcb7e","claim-8aed56fd0d6163c3109b","claim-9dcb1e69ff8f13d06582","claim-b15473954a299060abe7","claim-712a2adc50f898a90565","claim-3f403ca8c22c5899d986","claim-61a84b680142eb57b7c6","claim-f62dedcb6e26a988a130","claim-155724a820a9d0135a1b","claim-ad5d2df31b94c7474902","claim-8a063723840aee90a661","claim-cb46986acf0fab7c49e7"],"finding_ids":["F1"],"question":"What do clinicians need to see in RASolute 309’s PFS and OS results before using zoldonrasib plus daraxonrasib as a chemotherapy-free alternative to first-line gemcitabine plus nab-paclitaxel for metastatic KRAS G12D-mutated pancreatic adenocarcinoma?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers welcome a chemotherapy-free first-line possibility but await confirmation"},{"id":"section-2","level":2,"title":"One LinkedIn account asks why the control is GemNabTAX rather than mFOLFIRINOX or nalIRINOX"},{"id":"section-3","level":2,"title":"Accounts express access hopes rather than confirmed local availability"},{"id":"section-4","level":2,"title":"Beyond the trial population"},{"id":"section-5","level":3,"title":"Speakers use pretreated doublet activity and model biology to justify testing the hypothesis"},{"id":"section-6","level":3,"title":"Speakers pair benefit-focused management with explicit reasons to hold treatment"},{"id":"section-7","level":3,"title":"One episode explores prophylaxis preferences without establishing a settled regimen"},{"id":"section-8","level":3,"title":"Speakers emphasize molecular selection; one requires allele-level information"},{"id":"section-9","level":3,"title":"One speaker predicts rapid uptake and less time in clinic, with fitness and line-of-treatment qualifications elsewhere"},{"id":"section-10","level":3,"title":"Speakers see more work ahead while an episode emphatically favors the platform"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression free survival (PFS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T2","label":"Primary endpoint: Overall survival (OS)"},{"findings":[{"id":"F1","shared_claims":3}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":9},{"id":"F2","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-11T18:46:53.490918Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-11T20:16:28Z","record_hash":"b2b1900cfab6a00ff9ba5486719524f7f21003accdc81b42c574d45a431733a6","release_hash":"202ec535a94bcf0a65ed95069c537c9369a97be42c522bfd9715e4f2d407ff9f","report_id":"erudio-nct07805954","run_id":"dd5826dd-136c-403a-9d3f-2625fadab713","schema_version":"5.0","slug":"rasolute-309-nct07805954","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"The clinicians cited see RASolute 309 as a possible route away from chemotherapy, drawing on earlier doublet activity rather than evidence warranting treatment change. Its position relative to mFOLFIRINOX and nalIRINOX remains unestablished, and hopes for wider access do not confirm availability. Activity and rash observations largely concern earlier studies or broader daraxonrasib use; no results from the trial itself were available in the sources reviewed for this edition.","examples":[{"claim_id":"claim-cb46986acf0fab7c49e7","finding_id":"F1","identity_check":"npi_registry","month":"2026-07","region":"US","role":"Physician","source_type":"youtube","statement":"considers RASolute-309 one of the most exciting forthcoming studies and is very excited about its potential to improve outcomes for patients with KRAS G12D."}],"meta_description":"43 sources screened · 25 verified statements (8 from clinicians verified by NPI or staff page) from 25 sources · 3 findings. Updated Nov 11, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-11T20:16:28Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-11T21:00:00Z","kind":"routine","summary":"A summary sentence now uses the wording of the finding it summarizes."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":43},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 clinician view in the sources used in this report is not yet captured as evidence in this edition.","56 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 24 sources about other trials or topics are not included.","The sources reviewed for this edition are a selected public-discussion sample, not a representative survey of HCP opinion; repeated posts and relays do not establish independent agreement.","Some passages cannot be assigned to a named speaker. Participant lists, professional profiles and recurring transcript labels do not resolve those passages.","Much of the efficacy, toxicity, patient-reported-outcome and practical-management discussion concerns pretreated doublet cohorts or daraxonrasib in other settings. Those observations do not establish outcomes for the first-line RASolute 309 combination.","No exact-trial results publication or protocol document was available in the reviewed material. Regulatory and access statements are attributed to their sources and do not independently confirm approval, reimbursement or local availability of the doublet.","Several comments are personal experience, preclinical interpretation, cross-study comparison or prospective expectation. Unspecified cohorts and slightly differing numerical accounts prevent treating them as a single comparative dataset."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":6,"other":0,"podcast":1,"publication":0,"registry":1,"regulatory":0,"x_thread":12,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":24,"methods":1},"count":25,"evidence_window":{"end":"2026-10-16","start":"2026-04-16"},"retrieval_snapshot":"2026-11-11T17:51:00.364249Z","timeline":[{"count":1,"week":"2026-W16"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W26"},{"count":5,"week":"2026-W27"},{"count":4,"week":"2026-W28"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W31"},{"count":2,"week":"2026-W38"},{"count":6,"week":"2026-W41"},{"count":1,"week":"2026-W42"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT07805954:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07805954:context","quote_policy":"short_quote_link_out"},{"id":"openfda:13a65923-d072-4dac-8620-8eabbf8c3641:20260827","quote_policy":"short_quote_link_out"},{"id":"openfda:3aef8dbc-34d0-4150-89f0-3b16cf0fbfdb:20261026","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3mx4vopcdcv2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-qfkt3i5kooppuue5onesacut-3mx6pzp3tcc2j","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7478445952983506944","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7478824875424468992","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7479751074661376000","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7513163648236974080","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7513396189493448704","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7513726434969047040","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520428488047157248","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:aef922","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2045901951699726561:dc2f80f6-44ed-466d-8d53-283df10d9235","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2063293101989400635:90d9d39d-cc8e-4d42-a7a1-65d52ea60671","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2071008374003749239:90a774ea-d087-4887-bef3-930afb56a32e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072666714072813619:1fe232fc-c687-453d-a428-c9b2c60c6042","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072672471073878189:2979a34b-2e2f-4944-8fba-739e580fe9c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072672927367987705:15ec3614-c7ab-4f31-b6b8-7d07e13e2aca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073982918716993676:0d395f83-b75e-4ba7-81dc-f2712839935c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073984065070612826:75ebc89a-7ab5-46de-b745-05468bf0e2b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074477157359714767:27e75911-e39b-4db0-a40d-85765002eb44","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2078600697671524360:92e60a55-06a0-4991-8c15-616b309ce3d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099467620026044824:fe94b6c2-0fa6-4e35-b685-20210ac6823c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099523259566096711:6765f2c2-00dc-48ee-a710-94fdc22f2feb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100332958947151946:3a985f60-54a9-4854-978d-e7b9e5f26d8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107078507117371748:877c3f24-f84e-4fc3-8731-f3959e80fe3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107079359945470187:80aa4bee-286f-449e-b8e0-681a0f0d4cf6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107079539000312215:bc22c1ad-3058-4611-b0c3-51f64f0905f5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107081201479451054:f85552c8-0261-46d3-b3fa-05459ac808dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107084442833428583:f6caff0b-3143-4b80-81f3-3aacd98ab5ba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107120897744126463:180527d3-ca11-4097-a38c-e7507b19b21b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107127044245016620:43b454c7-3380-4409-9a7b-db89e6ff03a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107134347870720451:31d31ffc-37ee-4f78-bcce-4cbe4925f69f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107184046451175481:9869f9d0-6f92-46c5-b800-84b7252d2906","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107410979462213939:44541f76-4f40-4d5b-90b6-0e6db2a29d0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107611958870700366:a96be004-d41c-404f-9481-db55ce49ebec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108196446084186370:9a497b67-9f36-4723-b594-2eb3f6648e1e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109120781963948040:2be92094-d721-4a8f-932a-e623e6181433","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114398561052053675:fbfdc067-381c-477f-a3ad-b65599e1fcfc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114722545585045603:edb19370-77df-41d6-af6d-9acb40fea48d","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:9Tf81V6IL_I","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DbmJxfeDbcc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:WqKNb39fCyo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZxzZglAK4gU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:rQJkRVPsuoY","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":7,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":28,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":43},"count":43,"evidence_window":{"end":"2026-10-26","start":"2026-04-16"},"retrieval_snapshot":"2026-11-11T17:51:00.364249Z","timeline":[{"count":2,"week":"2026-W16"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W26"},{"count":5,"week":"2026-W27"},{"count":4,"week":"2026-W28"},{"count":2,"week":"2026-W29"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W31"},{"count":3,"week":"2026-W38"},{"count":19,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":3,"week":"2026-W44"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":11,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":6,"x_video":0,"youtube":7}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: daraxonrasib","status":"unmapped"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Abraxane"],"label":"nab-paclitaxel","slug":"nab-paclitaxel"},{"reason":"Unmapped registry intervention: zoldonrasib","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Pancreatic cancer","slug":"pancreatic-cancer"},{"reason":"Unmapped registry condition: Pancreatic Cancer Metastatic","status":"unmapped"},{"reason":"Unmapped registry condition: PDAC","status":"unmapped"},{"reason":"Unmapped registry condition: PDAC - Pancreatic Ductal Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Pancreatic Adenocarcinoma Metastatic","status":"unmapped"},{"reason":"Unmapped registry condition: Pancreatic Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Pancreatic Adenosquamous Carcinoma","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"RASolute 309","aliases":["RASolute 309","Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma","A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma"],"brief_title":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma"],"display_condition":"first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma","display_interventions":[["zoldonrasib","daraxonrasib"]],"enrollment":{"count":400,"type":"ESTIMATED"},"interventions":[{"name":"daraxonrasib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"nab-paclitaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"zoldonrasib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07805954","official_title":"A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2029-03","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by Investigator.","measure":"Progression free survival (PFS)","timeFrame":"Up to approximately 4 years"},{"description":"OS is defined as the time from randomization until death from any cause.","measure":"Overall survival (OS)","timeFrame":"Up to approximately 4 years"}],"registered_date":{"date":"2026-09-08","type":"ACTUAL"},"registry_last_updated":"2026-11-06","registry_url":"https://clinicaltrials.gov/study/NCT07805954","short_name":"RASolute 309","short_name_basis":"registry_acronym","sponsor":"Revolution Medicines, Inc.","start_date":{"date":"2026-08-28","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"RMC-9805-309","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}